Published by clickbroker.blogspot.com Pharmaceutical giant Eli Lilly & Co. (LLY) CEO John C. Lechleiter’s Wall Street Journal opinion <a[More...]

Garmin (GRMN) reported first quarter earnings of 25 cents a share, a 17 cent miss, as revenues declined 34.2% year-over-year to $437 million Agrium (AGU) reported first-quarter earnings of 4 cents a share, a 20 cent miss, as revenues jumped 58.4% year-over year to $1.75 billion.  The Company said it expects second ...

Against the backdrop of a possible launch of Microsoft Corp.’s (MSFT) new smartphone, federal regulators are now investigating if an overlap of directors on the boards of Apple Inc. (AAPL) and Google Inc. (GOOG) breach antitrust laws. The Silicon Valley giants share two directors on their boards, Eric Schmidt, chief executive of ...

I am saying "wow" a lot of late - Sequenom (SQNM) is out with something after hours I've never seen in all the years I've been doing stocks; a delay in their Down Syndrome test due to employee mishandling of data. The stock is down 50% after hours. Worse - this was our only long position I actually have a hedge against, but I covered it into the weakness early this week - basically have 50 shares short as a holding position. On the long side we only have a 1.4% stake since the stock chart has been awful but looks like that will be 0.7% by tomorrow. Not good - it's one thing to be hit by an earnings situation but this is out of left field. Here I thought this was my personal Dendreon (DNDN) - something I'd stick with in the long run, waiting for the magical day to arrive it goes up 200% in a session. Well, we will see what[More...]

Last year, the Biotech industry as a whole achieved a much better performance than the market. Both the NASDAQ Biotech Index and AMEX Biotech Index outperformed all three major market indices (Dow Jones Industrial Average, NASDAQ Composite and S&P 500) in a large margin. The major indices declined as much as 40% while the NASDAQ Biotech Index declined only 12.6% and the AMEX Biotech Index was down 17.7%. However, when the recession enters into its third year, the Biotech industry is not doing better than the market, which has been evident by the indices' performances. As of April 9, 2009, AMEX Biotech Index declined 3%, and the broader NASDAQ Biotech Index was down 6.8% (AMEX Biotech has 20 biotech companies while NASDAQ Biotech Index includes over 130 component companies). Although the Dow and S&P 500 also declined a similar percentage, technology-laden NASDAQ actually has a gain of 4.8%, which is more comparable to the biotech indices. See[More...]